A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer
Sponsor: Olema Pharmaceuticals, Inc.
This PHASE1/PHASE2 trial investigates HER2-negative Breast Cancer and Hormone Receptor Positive Breast Carcinoma and is currently completed. Olema Pharmaceuticals, Inc. leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2021 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Olema Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .